Skin cancer is the most common cancer in the United States.
Early detection of skin cancer can save lives, reduce healthcare costs, and improve overall patient outcomes. Until now, tools for early detection have been little more than glorified flashlights and cameras. Now there’s a new option: DermataScan - the only complete rapid assessment solution to skin cancer screening.
- 1 in 5 Americans will develop skin cancer by the age of 70
- More than 2 people die of skin cancer in the U.S. every hour
- Having 5 or more sunburns doubles your risk for melanoma
- When detected early, the 5-year survival rate for melanoma is 99%
Early detection of skin cancer can save lives, reduce healthcare costs, and improve overall patient outcomes. Until now, tools for early detection have been little more than glorified flashlights and cameras. Now there’s a new option: DermataScan - the only complete rapid assessment solution to skin cancer screening.
OTD Optical Transfer Diagnosis: At a Glance
The backbone of the DermataScan system is the DeepX OTD - Optical Transfer Diagnosis technology. With the DermataScan device, OTD illuminates a skin lesion from 12 directions to record spectral radiance images. The software uses accurate forward and inverse modeling of light transfer in skin tissue to infer skin properties in upper and lower dermis thickness, upper and lower melanin content, upper keratin content, and blood content and oxygenation in the dermis. These physiology properties and morphology parameters allow for diagnosis of the health of the skin tissue.
The backbone of the DermataScan system is the DeepX OTD - Optical Transfer Diagnosis technology. With the DermataScan device, OTD illuminates a skin lesion from 12 directions to record spectral radiance images. The software uses accurate forward and inverse modeling of light transfer in skin tissue to infer skin properties in upper and lower dermis thickness, upper and lower melanin content, upper keratin content, and blood content and oxygenation in the dermis. These physiology properties and morphology parameters allow for diagnosis of the health of the skin tissue.
The DeepX algorithm discriminates between benign and malignant lesions using neural network technology, cost function optimization for determination of optical diagnostic weights, generalized diagnostic parameters and indications defined by a team of dermatologic experts. It is superior to trained physicians and expert dermatologists in detecting skin cancer. It is also superior in ruling out melanoma.
DermataScan instrument
Based on Optical Transfer technology, the DermataScan provides skin cancer diagnosis based on subsurface information of the suspected mole or lesion, without harvesting a single cell from the patient.
This pain-free cancer screening is a breakthrough in non-invasive diagnosis using tele-dermatology. Each scan is reviewed and assessed by a US-based board-certified dermatologist, with a full report provided to the primary care physician in as little as 48-72 hours.
Based on Optical Transfer technology, the DermataScan provides skin cancer diagnosis based on subsurface information of the suspected mole or lesion, without harvesting a single cell from the patient.
This pain-free cancer screening is a breakthrough in non-invasive diagnosis using tele-dermatology. Each scan is reviewed and assessed by a US-based board-certified dermatologist, with a full report provided to the primary care physician in as little as 48-72 hours.
Seeing beyond the surface for accurate assessment
The DermataScan DermoSight scanner is the only device that captures a dermascopic image as well as 7 pathophysiology views below the skin’s surface, showing the disorganization of a suspicious mole or lesion. All other dermascopes, cameras, and imaging methods capture skin-level only. This allows dermatologists to make a more accurate assessment based on the underlying physiology of the skin.
The DermataScan DermoSight scanner is the only device that captures a dermascopic image as well as 7 pathophysiology views below the skin’s surface, showing the disorganization of a suspicious mole or lesion. All other dermascopes, cameras, and imaging methods capture skin-level only. This allows dermatologists to make a more accurate assessment based on the underlying physiology of the skin.
DermataScan on DeepX: A robust platform for in-practice and telemedicine
The DermataScan system has a Patient Management System designed by dermatologists to capture all relevant information to aid a dermatologist with a rapid assessment. The DermataScan DeepX patient management system integrates with current EMR platforms.
Early detection is taken to the next leve with DeepX a secure, HIPPA-compliant, cloud-based telemedicine platform and patient management system that seamlessly integrates with EMRs – it is where patient profiles can be created, updated and stored for up to 10 years. We deploy the latest in security measures, engage in rigorous third-party threat testing and real-time monitoring.
This system can be deployed in a variety of clinical settings, from stand-alone real-time use in a dermatology practice to scanning in multiple PCP environments with offsite reading and validation by a board-certified dermatologist, populating to a patient’s EMR within 24 hours.
The DermataScan system has a Patient Management System designed by dermatologists to capture all relevant information to aid a dermatologist with a rapid assessment. The DermataScan DeepX patient management system integrates with current EMR platforms.
Early detection is taken to the next leve with DeepX a secure, HIPPA-compliant, cloud-based telemedicine platform and patient management system that seamlessly integrates with EMRs – it is where patient profiles can be created, updated and stored for up to 10 years. We deploy the latest in security measures, engage in rigorous third-party threat testing and real-time monitoring.
This system can be deployed in a variety of clinical settings, from stand-alone real-time use in a dermatology practice to scanning in multiple PCP environments with offsite reading and validation by a board-certified dermatologist, populating to a patient’s EMR within 24 hours.
Become a part of the skin cancer screening solution
Early adoption of this technology and platform is happening around the world. Now, the time has come for patients in the US to benefit from this revolutionary system with DermataScan.
This technology is not limited to clinical practice. We have developed a mobile screening environment that can be deployed easily at any location. Starting in the spring of 2023, we are implementing mobile screening in retirement communities and long term care facilities.
Please contact us today to find out how you and your practice can take part in this ground-breaking technology.
Early adoption of this technology and platform is happening around the world. Now, the time has come for patients in the US to benefit from this revolutionary system with DermataScan.
This technology is not limited to clinical practice. We have developed a mobile screening environment that can be deployed easily at any location. Starting in the spring of 2023, we are implementing mobile screening in retirement communities and long term care facilities.
Please contact us today to find out how you and your practice can take part in this ground-breaking technology.
US Distribution & Contact Information:
VERIOSYS TECHNOLOGIES, INC.
6822 22nd Ave N • Suite 308
Saint Petersburg, Florida 33710
(844) 828-7837
www.veriosys.com
VERIOSYS TECHNOLOGIES, INC.
6822 22nd Ave N • Suite 308
Saint Petersburg, Florida 33710
(844) 828-7837
www.veriosys.com